Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (360)	1/19/2016 3:59:16 PM
From: scaram(o)uche	Respond to of 684

and just for symmetry to the cmrx posts, here's the latest abstract on eravacycline. I like this one, as there are no ttph authors. :-) Antimicrob Agents Chemother. 2015 Dec 14. pii: AAC.02403-15. [Epub ahead of print]Activity of Eravacycline against Escherichia coli Clinical Isolates from U.S. Veterans (2011) in Relation to Co-resistance Phenotype and Sequence Type 131 Genotype. Johnson JR1, Porter SB2, Johnston BD3, Thuras P3. Author information 1VA Medical Center, Minneapolis, MN, and University of Minnesota, Minneapolis, MN VA Medical Center, Minneapolis, MN, and University of Minnesota, Minneapolis, MN johns007@umn.edu. 2VA Medical Center, Minneapolis, MN, and University of Minnesota, Minneapolis, MN. 3VA Medical Center, Minneapolis, MN, and University of Minnesota, Minneapolis, MN VA Medical Center, Minneapolis, MN, and University of Minnesota, Minneapolis, MN. Abstract Eravacycline is a novel broad-spectrum fluorocycline with potent Gram-negative activity, including for multidrug-resistant strains. Among 472 Escherichia coli clinical isolates from 24 Veterans Affairs medical centers (2011), divided equally as susceptible vs. resistant to fluoroquinolones, broth microdilution eravacycline MICs were distributed unimodally, ranging from 0.03 to 1.0 µg/mL (MIC50 0.125 µg/mL, MIC90 0.25 µg/mL). EravacyclineMICs were ~2-fold higher among fluoroquinolone-resistant, gentamicin-resistant, multidrug-resistant, and sequence type 131 (ST131) isolates (P < 0.01 for each comparison).